News and Announcements
US Residential Fund Successfully Sold Properties in Accordance with New Strategic Direction
- Published February 07, 2017 9:14AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
US Residential Fund (USR) is pleased to announce the sale of 28 single family houses in Atlanta, Georgia. These specific properties were sold for US$3.95 million consistent with fair value.
As a result of these sales, the Fund has paid down US$2.2 million in relation to debt.
Prior to this transaction, the USR held 122 single family rental properties across the states of Georgia, Ohio and Texas.
To view USR’s graph in relation to pre- and post-sale along with a comment for the Managing Director please click here.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
